Expression and distribution of voltage-gated sodium channels in the cerebellum

被引:105
|
作者
Schaller, KL [1 ]
Caldwell, JH [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA
来源
CEREBELLUM | 2003年 / 2卷 / 01期
关键词
channel isoforms; Purkinje cell dendrites; radial glia; developmental expression;
D O I
10.1080/14734220309424
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In order to understand the effects of sodium channels on synaptic signaling and response in the cerebellum, it is essential to know for each class of neuron what sodium channel isoforms are present, and the properties and distribution of each. Sodium channels are heteromultimeric membrane proteins, consisting of a large alpha subunit that forms the pore, and one or more beta subunits. Ten genes encode an alpha subunit in mammals, and of these, four are expressed in the cerebellum: Na(v)1.1, Na(v)1.2, Na(v)1.3 and Na(v)1.6. Three genes encode beta subunits (Nabeta1-3), and all three are expressed in the cerebellum. However, Na(v)1.3 and Nabeta3 have been found only in the developing cerebellum. All sodium channels recorded in the cerebellum are TTX-sensitive with similar kinetics, making it difficult to identify the isoforms electrically. Thus, most of the expression studies have relied on techniques that allow visualization of sodium channel subtypes at the level of mRNA and protein. In situ hybridization and immunolocalization studies demonstrated that granule cells predominantly express Na(v)1.2, Na(v)1.6, Nabeta1, and Nabeta2. Protein for Na(v)1.2 and Na(v)1.6 is localized primarily in granule cell parallel fibers. Purkinje cells express Na(v)1.1, Na(v)1.6, Nabeta1 and Nabeta2. The somato-dendritic localization of Na(v)1.1 and Na(v)1.6 in Purkinje cells suggests that these isoforms are involved in the integration of synaptic input. Deep cerebellar nuclei neurons expressed Na(v)1.1 and Na(v)1.6 as well as Nabeta1. Bergmann glia expressed Na(v)1.6, but not granule cell layer astrocytes. Some sodium channel isoforms that are not expressed normally in the adult cerebellum are expressed in animals with mutations or disease. Electrophysiological studies suggest that Na(v)1.6 is responsible for spontaneous firing and bursting features in Purkinje cells, but the specialized functions of the other subunits in the cerebellum remain unknown.
引用
收藏
页码:2 / 9
页数:8
相关论文
共 50 条
  • [1] Expression and distribution of voltage-gated sodium channels in the cerebellum
    Kristin L. Schaller
    John H. Caldwell
    The Cerebellum, 2003, 2 : 2 - 9
  • [2] Developmental expression of voltage-gated potassium channels in mouse cerebellum
    Nakahira, K
    Shibata, R
    Shibasaki, K
    Ikenaka, K
    JOURNAL OF NEUROCHEMISTRY, 1999, 73 : S130 - S130
  • [3] Voltage-gated sodium channels
    Kwong, Kevin
    Carr, Michael J.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 22 : 131 - 139
  • [4] Trafficking and cellular distribution of voltage-gated sodium channels
    Cusdin, Fiona S.
    Clare, Jeffrey J.
    Jackson, Antony P.
    TRAFFIC, 2008, 9 (01) : 17 - 26
  • [5] Immunohistochemical study on the distribution of the voltage-gated potassium channels in the gerbil cerebellum
    Chung, YH
    Joo, KM
    Nam, RH
    Kim, YS
    Lee, WB
    Cha, CI
    NEUROSCIENCE LETTERS, 2005, 374 (01) : 58 - 62
  • [6] Immunohistochemical study on the distribution of the type I and type II voltage-gated sodium channels in the gerbil cerebellum
    Chung, YH
    Shin, CM
    Kim, MJ
    Cha, CI
    NEUROSCIENCE LETTERS, 2000, 293 (01) : 25 - 28
  • [7] Distribution and function of voltage-gated sodium channels in the nervous system
    Wang, Jun
    Ou, Shao-Wu
    Wang, Yun-jie
    CHANNELS, 2017, 11 (06) : 534 - 554
  • [8] Voltage-gated sodium channels and hyperalgesia
    Lai, J
    Porreca, F
    Hunter, JC
    Gold, MS
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2004, 44 : 371 - 397
  • [9] Voltage-gated sodium channels in epilepsy
    Köhling, R
    EPILEPSIA, 2002, 43 (11) : 1278 - 1295
  • [10] Voltage-Gated Sodium Channels and Pain
    Priestley, T.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (06) : 441 - 456